Weight Loss Drug Wegovy May Decrease Risk of Stroke and Heart Attack, Drugmaker Says
as an indicator of health, but in the case of these drugs, it’s a crucial part of the FDA guidelines) and being in the 95“This drug works by sending satiety signals to your brain and slowing down your GI tract, effectively making you feel fuller longer,” Alan says. “It does have many modes of action, in addition to these major modes of action.”Again, the study hasn’t been peer-reviewed or published yet.
For the study, patients were either given shots once a week of Wegovy or a placebo, along with the standard of care to prevent major cardiovascular events over a period of five years. The trial found that people who took Wegovy had a “statistically significant and superior reduction” in the risk of major adverse cardiovascular events compared to the placebo, Novo Nordisk says.That’s the big question, and experts say it’s tricky to figure out without seeing the full study.
“We know that [excess] weight itself is a risk factor for heart disease, but it’s one of many different risk factors,” says, an interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA. Alan agrees, noting that “the weight loss it produces is likely a large part of reducing risk.”
But Dr. Chen says that it’s “a little surprising” that weight loss itself would improve cardiovascular risk factors by as much as 20%. Worth noting: Novo Nordisk didn’t share how much weight the study participants lost. Experts say there’s likely more to this than just weight loss, though. “There must be some other effect on blood sugar control that hasn’t been studied yet,” Dr. Chen says.Novo Nordisk says in its press release that the drug was “safe and well-tolerated” in the latest study. However, Wegovy and similar semaglutide medications have been linked with gastroparesis, i.e. stomach paralysis, per.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Weiterlesen »
Weight loss drug Wegovy cuts risk of stroke and heart attack, maker saysThe findings show that the weight-loss drug Wegovy has medical benefits beyond weight reduction, potentially leading to insurance coverage. Dr. Shauna Levy, a specialist in obesity medicine, believes the results are compelling.
Weiterlesen »
Weight Loss Drug Wegovy May Help Prevent Heart AttacksA new study found that people who received the weight loss drug semaglutide (whose brand name is Wegovy) showed a significant 20% reduction in heart-related deaths, heart attacks, or strokes.
Weiterlesen »
Novo Nordisk extends U.S. supply curbs on weight-loss drug WegovyNovo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand.
Weiterlesen »
Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soarThe Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.
Weiterlesen »
Wegovy-maker Novo Nordisk extends curb on supply of weight-loss drug, raises outlookThe Danish drugmaker confirmed that it will continue to restrict the lower-dose strengths of Wegovy as it strives to keep up with demand.
Weiterlesen »